Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555152 · ClinicalTrials.gov registry record · NA
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
A NA study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT00555152: Completed NA study, sponsored by National Cancer Institute (NCI).
NCT00555152 is a NA study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555152, a NA study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Lapatinib Ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-08-19 |
| Est. Completion | 2014-08-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555152
The ClinicalTrials.gov registry entry for NCT00555152 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00555152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00555152 about?
NCT00555152 is a clinical study titled "Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ". This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00555152?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2009-08-19. Estimated completion is 2014-08-28.
What interventions are being tested in trial NCT00555152?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Lapatinib Ditosylate (DRUG).
Who is sponsoring clinical trial NCT00555152?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.